Menu
Log in



Your Resource for Neurotherapeutics Discovery and Development


Upcoming events

    • September 23, 2025
    • October 27, 2025
    • 11:59 PM
    • Hyatt Regency Bethesda, Bethesda MD
    Register

    Submitting an Abstract to ASENT

    Deadline: October 27, 2025 at 11:59PM ET

    The Abstract Review Committee is committed to presenting the best in neurotherapeutic research at the ASENT Annual Meeting. All abstracts are evaluated by experts in neurotherapeutics according to the following criteria and overall merit:

    1. Scientific or clinical impact
    2. Quality of data, analysis, and presentation
    3. Relevance to the discovery and/or development of neurotherapeutics and inclusion of novel targets or new initiatives.
    4. Abstracts must be submitted, presented, and cited in English.

    The abstract should describe original research broadly relevant to the goal of ASENT, which is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system. Please check your abstract carefully for typographical errors, misspellings, etc. Be sure to include data results.

    FAQs on Eligibility

    • ASENT welcomes Encore Abstracts, or those abstracts that have been previously presented at other recent scientific meetings, or submitted for consideration to other scientific meetings.
    • Trainees and early career researchers are encouraged to submit
    • All sectors (academic, industry, government, etc.) are welcome to submit
    • Trial Designs or Trials in Progress are welcome and considered 
    • Case Studies or Case Reports will not be considered

    If Accepted

    One presenting author must be designated to attend the Annual Meeting in person. All attendees must register to attend the meeting via asent.org separate from this form. 

    Poster Presentations
    If your abstract is selected for a poster, you will need to be available to participate in our poster presentation at the annual meeting. This is scheduled to take place on Wednesday, March 4, 2026 at 5pm.

    Oral Presentations
    Submitted abstracts that most closely conform to the above criteria, and the ASENT goals, may also be selected for a 10-minute oral presentation (including 2 minute Q&A) at our Oral  Presentation session. ASENT encourages abstracts from private, public and startup companies and government or academic labs that contain neurotherapeutic research results.

    About the Meeting
    The ASENT Annual Meeting attracts a broad spectrum of researchers, clinicians, investors, and other leaders in neurotherapeutics from all over the world, in all neurologic disease states. Oral presentations increase exposure to strategic partners in life sciences who have supported novel approaches through partnerships or strategic investments.

    For questions regarding abstracts, please email jessica@asent.org.

    • March 02, 2026
    • 8:00 AM
    • March 06, 2026
    • 1:00 PM
    • Hyatt Regency Bethesda, Bethesda, MD
    Register

    ABOUT ASENT 2026 Annual Meeting
    and Clinical Trials Course

    The ASENT 2026 Annual Meeting, the premier neurotherapeutics conference will take place March 2 - 6, 2026 at the Hyatt Regency Bethesda in Bethesda, MD. This scientific meeting is where senior leaders from leading payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers gather with one central focus, improving the process of bringing neurotherapeutics to market.

    ASENT's popular Neurotherapeutic Clinical Trials Course runs March 2-3. Followed by the ASENT 2026 Annual Meeting, which runs March 4-6, all in one location.

    Attendees interested in participating in both the Clinical Trials Course and Annual Meeting are encouraged to select the appropriate registration level and then add on the clinical trials course during the registration process for an additional $150.

    The plenary sessions, panel discussions, outstanding pipeline presentations and poster sessions focus on the latest science in neurotherapeutics. The conference content will focus on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, satellite luncheons, networking meetings, pipeline presentations and poster sessions.

    WHO ATTENDS

    Chief Medical Officers | Chief Scientific Officers Clinician-Investigators Clinical Research Professionals | Clinical Scientists | Clinical Trial Unit Directors CROs Drug Discovery Neuroscientists | Founders Funders Innovation Centers Investors / Venture Capital | Journal Editors Medical Directors | MSLs | Patient Advocates | Regulatory Science Professionals | Research Scientists | Trainees (Basic, Clinical, Translational)

    Cancellation Policy

    You may cancel your registration for a refund through February 1, 2026 by contacting our offices directly. Cancellations will be refunded less a $50 cancellation fee. No refunds will be granted for cancellations on February 15, 2026 and after.

Powered by Wild Apricot Membership Software